Development of Patient-Derived Colorectal Cancer Xenograft and Organoid Models with Acquired Resistance to KRAS G12C Inhibitors

被引：0
|
作者：
Hua, L. [1 ]
Zheng, J. [2 ]
Wang, J. [1 ]
Shang, L. [3 ]
Qian, W. [4 ]
Sun, Y. [3 ]
Bourre, L. [5 ]
Wang, J. [1 ]
机构：
[1] Crown Biosci Inc, Canc Pharmacol, San Diego, CA USA
[2] Crown Biosci Inc, Oncol In Vivo, San Diego, CA USA
[3] Crown Biosci Inc, In Vivo, San Diego, CA USA
[4] Crown Biosci Inc, Data Sci & Bioinformat, San Diego, CA USA
[5] Crown Biosci Inc, Res & Innovat, San Diego, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114789
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB262
引用
收藏
页码：S104 / S105
页数：2
相关论文
共 50 条
  • [31] Secondary KRAS G12C Mutation and Acquired BRAF Inhibitor Resistance in a Patient with Papillary Thyroid Cancer: A Case Report
    Sham, S.
    Bendari, A.
    Seetharamu, N.
    Vele, O.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (11): : S136 - S136
  • [32] Resistance looms for KRAS G12C inhibitors and rational tackling strategies
    Zhang, Junmin
    Zhang, Juanhong
    Liu, Qing
    Fan, Xing-Xing
    Leung, Elaine Lai-Han
    Yao, Xiao-Jun
    Liu, Liang
    PHARMACOLOGY & THERAPEUTICS, 2022, 229
  • [33] Clinical Data for KRAS G12C Inhibitors
    Kim, H. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S95 - S96
  • [34] The promise and peril of KRAS G12C inhibitors
    Moore, Amanda R.
    Malek, Shiva
    CANCER CELL, 2021, 39 (08) : 1059 - 1061
  • [35] Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
    Kale, Ramesh
    Samant, Charudatt
    Nandakumar, Krishnadas
    Pai, K. Sreedhara Ranganath
    Bhonde, Mandar
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2025, 760
  • [36] Development of a panel of breast cancer patient-derived xenograft models (PDX) with estrogen independence and/or acquired resistance to endocrine treatment
    de Boisferon, Marc Hillairet
    Benzaid, Ismahene
    Chatel, Elodie Marie Dit
    Hoffmann, Nicolas
    Littlefield, Bruce
    CANCER RESEARCH, 2020, 80 (16)
  • [37] Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
    Qunaj, Lindor
    May, Michael S.
    Neugut, Alfred I.
    Herzberg, Benjamin O.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [38] Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
    Yaeger, Rona
    Weiss, Jared
    Pelster, Meredith S.
    Spira, Alexander, I
    Barve, Minal
    Ou, Sai-Hong, I
    Leal, Ticiana A.
    Bekaii-Saab, Tanios S.
    Paweletz, Cloud P.
    Heavey, Grace A.
    Christensen, James G.
    Velastegui, Karen
    Kheoh, Thian
    Der-Torossian, Hirak
    Klempner, Samuel J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (01): : 44 - 54
  • [39] Treatment-refractory colorectal cancer with KRAS G12C mutation
    Hartmann, Milan J. M.
    Alakus, Hakan
    ONKOLOGIE, 2024, : 521 - 522
  • [40] Utility of Patient-Derived Xenograft and Xenograft-Derived Organoid Models with EGFR Mutation to Study EGFR-TKI Resistance
    Koga, T.
    Pham, N-A
    Rosen, J.
    Li, Q.
    Arivajiagane, A.
    Hueniken, K.
    Khan, S.
    Khalil, M.
    Radulovich, N.
    Shepherd, F. A.
    Yasufuku, K.
    Liu, G.
    Tsao, M-S
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S158 - S159
12345